CurrentUnitedHealthcarePolicy 2026T0627K

Sympathetic blockade (celiac plexus, splanchnic, stellate ganglion, superior hypogastric plexus) — Coverage Criteria

This policy governs UnitedHealthcare Commercial and Individual Exchange coverage determinations for sympathetic blockade procedures (e.g., celiac plexus, splanchnic, stellate ganglion, superior hypogastric plexus) and identifies indications considered medically necessary or not medically necessary.

Policy Summary

PayerUnitedHealthcare

PolicySympathetic blockade — Coverage Criteria

Policy CodePolicy 2026T0627K

Change TypeRoutine review

Effective DateJan 1, 2026

Next Review Date

Key ActionSubmit required medical records and plan-specific authorization documentation to support InterQual-based clinical criteria for listed sympathetic blockade procedure codes.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4procedure CPT codes listed

2indications proven/medically necessary

2indications unproven/not medically necessary

InterQualclinical criteria referenced

Coverage Criteria for Sympathetic Blockade

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered and Not Medically Necessary Indications

Coverage stance based on indication groups

Medically necessary indications: Sympathetic blockade is proven and medically necessary for pancreatic cancer with severe abdominal or back pain AND for complex regional pain syndrome (CRPS).

Refer to InterQual CP: Procedures, Sympathetic Blockade for clinical coverage criteria.

Not medically necessary (unproven) indications: Sympathetic blockade is unproven and not medically necessary for chronic pancreatitis AND for chronic abdominal or back pain.

Evidence insufficient to establish safety and efficacy for these indications.

Sympathetic blockade performed for chronic pancreatitis and for chronic abdominal or back pain is designated as unproven and not medically necessary. This policy lists these specific indications as not medically necessary and therefore not covered under the policy criteria.

Coverage decisions for the procedures described (e.g., celiac plexus, splanchnic, stellate ganglion, superior hypogastric plexus injections) should follow the policy’s stated medical necessity determinations and any referenced clinical criteria (InterQual) when evaluating other indications.

The rationale for classifying sympathetic blockade as not medically necessary for these chronic noncancer pain conditions is based on insufficient and mixed evidence for durable benefit and potential procedural risks. Systematic reviews and studies report variable and often short-term pain relief, limitations from small sample sizes and study heterogeneity, and occurrence of adverse events ranging from transient symptoms to serious complications.

Because long-term effectiveness and safety have not been established by well‑designed, large randomized trials with extended follow-up, the evidence does not support routine coverage of sympathetic blockade for chronic pancreatitis or chronic abdominal or back pain.

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization and Clinical Criteria

Prior authorization and coverage determinations for sympathetic blockade and neurolytic interventions are governed by UnitedHealthcare clinical criteria (for example, InterQual) and any applicable prior authorization requirements. Providers should verify member eligibility and obtain any required prior authorization before scheduling services.

Prior authorization may be required per the member specific benefit plan and InterQual criteria.
Coverage is subject to the member's benefit plan document; in a conflict, the member specific benefit plan governs.

Note

Use After Failure of Other Treatments (Clinical Context)

Neurolytic interventions (for example, celiac plexus block, splanchnic nerve ablation) should generally be considered only after other appropriate medical, endoscopic, or surgical treatments have failed, consistent with guideline recommendations for chronic pancreatitis and related indications.

Use of neurolytic interventions is supported for selected patients with painful chronic pancreatitis who have failed endoscopic and surgical treatments.
Document prior trials of medical, endoscopic, and surgical therapies and the clinical rationale for progressing to neurolytic intervention.

Documentation Required

Medical Records and Plan Documents Required

Medical records and plan documents may be required to determine whether the member meets clinical criteria and to adjudicate coverage. Furnish complete documentation at time of review to avoid delays or denials.

Provide relevant medical records including history of presenting condition, prior treatments tried (medical, endoscopic, surgical), responses to therapy, imaging, pain assessments, and opioid/analgesic use.
Include the member specific benefit plan document or reference to the benefit limits/exclusions when applicable.
Failure to provide required documentation or evidence that services are excluded under the member's benefit plan may result in denial of the request.

Denial Risk

Documentation Deficiencies May Trigger Denial

Lack of required clinical documentation or evidence that the service is excluded under the member specific benefit plan may result in denial of prior authorization or payment. Ensure submitted records clearly demonstrate that coverage criteria and plan provisions are met.

Incomplete records, missing documentation of failed conservative/endoscopic/surgical treatments, or absence of a medical necessity rationale are common grounds for denial.
If the member's benefit plan excludes the service, coverage will be denied regardless of clinical documentation.

Background on Sympathetic Blockade

Sympathetic blockade refers to percutaneous or endoscopic injections of local anesthetic (with or without neurolytic agents) targeted to autonomic ganglia or sympathetic chains to reduce visceral or sympathetically mediated pain.

Typical procedural targets include the celiac plexus and splanchnic nerves for upper abdominal and pancreatic pain, the stellate ganglion for head/neck and upper extremity sympathetically maintained pain, and the superior hypogastric plexus for pelvic pain. These procedures may be performed with or without radiologic monitoring depending on clinical approach.

Definitions

Celiac plexus block (CPB) / Splanchnic nerve block — definition and example CPT references

DefinitionInjection of an anesthetic agent into the celiac plexus or splanchnic nerves to manage abdominal or visceral pain.

Common CPT examples64530 — Injection, anesthetic agent; celiac plexus, with or without radiologic monitoring.

Related CPT codes (thoracic/lumbar/sympathetic)64520 — Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic).

Related CPT code (pelvic plexus)64517 — Injection, anesthetic agent; superior hypogastric plexus.

Related CPT code (cervical sympathetic)64510 — Injection, anesthetic agent; stellate ganglion (cervical sympathetic).

Prior Conservative Therapies

Use after other therapies have failed (per guideline context)

Required prior treatment context before considering neurolytic sympathetic interventions

Guideline-based conservative treatment requirement: Neurolytic interventions (e.g., celiac plexus block, splanchnic denervation) should be considered only for selected patients with chronic pancreatitis who have failed medical, endoscopic, and surgical treatments.

Follow multidisciplinary approach; behavioral interventions and assessment of opioid status are recommended per guideline.

Not Covered / Not Medically Necessary Services

Not covered: sympathetic blockade procedures performed specifically for chronic pancreatitis and for chronic abdominal or back pain are explicitly listed as unproven and not medically necessary under this policy and are therefore not covered for those indications.

Providers should refer to the policy’s covered indications and relevant clinical criteria when assessing alternative indications or when submitting prior authorization requests for sympathetic blockade procedures.